Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2011-12-23 | Pharming (The Netherlands) | €8.4 million | private convertible bond | undisclosed institutional investors | Rare diseases - Genetic diseases | Fundraising |
2011-12-23 | Tigenix (Belgium) | € 2.9 million | grant | Regenerative medicine | Grant | |
2011-12-22 | PTC Therapeutics (UK) | $5 million | grant | The Wellcome Trust (UK) | Infectious diseases | Grant |
2011-12-19 | Argen-X (The Netherlands-Belgium) | €1.3 million | grant | Flemish agency for Innovation by Science and Technology (IWT) (Belgium) | Cancer - Oncology - Autoimmune diseases | Grant |
2011-12-19 | Cellprothera (France) | € 2.5 million | financing round | R2M (France)- SODIV Alsace (France) | Cardiovascular diseases | Fundraising |
2011-12-19 | Atox Bio (Israel) | $3.25 million (€2.5 million) | financing round | Esperante Ventures (UK) | Inflammatory diseases | Fundraising |
2011-12-19 | to-BBB (The Netherlands) | €600,000 | grant | Agentschap NL (The Netherlands) | Cancer - Oncology - Neurodegenerative diseases - Cardiovascular diseases | Grant |
2011-12-12 | CYTOO (France), Cenix BioScience (Germany), three academic partners | €4 million | grant | European Commission’s Seventh Framework Program (FP7) | Technology - Services | Grant |
2011-12-08 | Arcarios (The Netherlands) | first tranche of a € 4.5 million loan | loan | Inflammatory diseases - Rheumatic diseases | Establishment of a new subsidiary in the EU | |
2011-12-08 | Verona Pharma (UK) | £3.25 million (€3.8 million) | private placement | Inflammatory diseases - Respiratory diseases | Private placement | |
2011-12-08 | ENKAM Pharmaceuticals (Denmark) and Enkam-led consortium, NeuroFGL | €6.0 million | grant | Neurodegenerative diseases | Grant | |
2011-12-08 | Agennix (Germany) | € 27.5 million | capital increase | dievini Hopp BioTech (Germany) - shareholders | Cancer - Oncology | Capital increase |
2011-12-07 | EMBL Ventures (Germany) | €40 million | Subvention | |||
2011-12-06 | TopiVert (UK) | £8 million (€9.3 million) | financing round | Inflammatory diseases - Ophtalmological diseases - Allergic diseases - Respiratory diseases | Fundraising | |
2011-12-04 | Argen-X (The Netherlands-Belgium) | € 32.5 million | series B financing round | OrbiMed Advisors (USA) - Seventure Partners (France) - Forbion Capital Partners (The Netherlands)- Credit Agricole Private Equity (France) - LSP (the Netherlands-Germany-USA) - BioGeneration Ventures (The Netherlands) - The Erasmus Biomedical Fund (The Netherlands) - Thuja Capital (The Netherlands) - VIB (Belgium) - PMV (Belgium) | Autoimmune diseases - Cancer - Oncology | Fundraising |
2011-12-02 | Discuva (UK) | undisclosed | financing round | New Wave Ventures LLP (UK) | Infectious diseases | Fundraising |
2011-12-01 | Prosensa (The Netherlands) | $1.5 million (€1.18 million) | grant | Charley’s Fund (USA) | Rare diseases - Neuromuscular diseases | Grant |
2011-11-28 | Targovax (Norway) | 9 million NOK (€1.1 million) | grant | Innovation Norway OFU-program (Norway) | Cancer - Oncology | Grant |
2011-11-21 | Cytoo (France) | €7 million ($10 million) | series C financing round | Sham (France) - Entrepreneurs Fund (EF) (France) - AURIGA Partners (France) - Jacques Lewiner, co-founder and president of the supervisory board at CYTOO. |
Technology - Services | Fundraising |
2011-11-17 | Biocartis (Belgium) | € 71 million (USD 100 million) | Series C equity fund raising | Debiopharm Group (Switzerland) - Philips (The Netherlands) - Johnson & Johnson Development Corporation (JJDC) (USA) - the Wellcome Trust (UK) - Korys (investment holding of the Colruyt family) (Belgium) Valiance Biovest, the family office of Dr Paul Janssen IHL SA (Luc Verelst) PMV New Rhein Healthcare certain members of the Biocartis senior management team the family office of founder Rudi Pauwels (Benaruca). |
Infectious diseases | Fundraising |